Full Name
Mrs. Laurence Albiges MD, PhD
Job Title
Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France
Company
Gustave Roussy
Speaker Bio
Laurence Albiges, M.D., Ph.D., is full professor of Medical Oncology at Paris Saclay University and is the Head of the Medical Oncology department at Gustave Roussy, Villejuif, France.
Her main field of interest across genitourinary tumours is new targets in renal cell carcinoma and non-clear cell renal carcinoma. She contributes to numerous other research endeavours, with over 250 articles published in peer-reviewed journals.
From 2015 to 2021, she chaired the Genito-Urinary Group at Gustave Roussy and subsequently took on the Medical Oncology departement head role.
She serves as GETUG board member, as well as ESMO Faculty coordinator for GU tumor – non prostate.
She is an ASCO member and was awarded several ASCO Merit Awards for her work.
She is a member of both the EAU RCC guidelines panel and ESMO RCC guidelines panel.
Her main field of interest across genitourinary tumours is new targets in renal cell carcinoma and non-clear cell renal carcinoma. She contributes to numerous other research endeavours, with over 250 articles published in peer-reviewed journals.
From 2015 to 2021, she chaired the Genito-Urinary Group at Gustave Roussy and subsequently took on the Medical Oncology departement head role.
She serves as GETUG board member, as well as ESMO Faculty coordinator for GU tumor – non prostate.
She is an ASCO member and was awarded several ASCO Merit Awards for her work.
She is a member of both the EAU RCC guidelines panel and ESMO RCC guidelines panel.
Speaking At
Think Tank Session (by invitation only)
Session 2: Classifying RCC - A Panel Approach
Q & A
ORAL ABSTRACT: Efficacy by baseline characteristics in the phase 3 LITESPARK-005 study of belzutifan versus everolimus for previously treated advanced clear-cell renal-cell carcinoma (ccRCC)
Debate: Combinations of Immune Checkpoint Inhibitors or IO TKI in Intermediate and Poor Risk Patients
Non-CME Industry Symposium: aRCC: Is your decision-making up-to-date? - Presented by Ipsen
Young Investigators Breakfast
Vogelzang Award
Non-CME Industry Symposium: Answering the Unanswered – Presented by Eisai
Session 17: Practice Changing Papers
Panel Discussion and Q & A
Session 2: Classifying RCC - A Panel Approach
Q & A
ORAL ABSTRACT: Efficacy by baseline characteristics in the phase 3 LITESPARK-005 study of belzutifan versus everolimus for previously treated advanced clear-cell renal-cell carcinoma (ccRCC)
Debate: Combinations of Immune Checkpoint Inhibitors or IO TKI in Intermediate and Poor Risk Patients
Non-CME Industry Symposium: aRCC: Is your decision-making up-to-date? - Presented by Ipsen
Young Investigators Breakfast
Vogelzang Award
Non-CME Industry Symposium: Answering the Unanswered – Presented by Eisai
Session 17: Practice Changing Papers
Panel Discussion and Q & A